Thirty-nine-year-old man in Hong Kong believed to have had underlying condition. Death is only second outside mainland China

• China’s leadership admits ‘shortcomings’ in coronavirus response
• Coronavirus: British evacuee falls ill during flight from China
• How to protect yourself
• Hundreds of Canadians await evacuation flight from Wuhan

7.14am GMT

From gassy passengers to viral anthems: how Beijing is seeking to lighten the mood amid the coronavirus crisis. This includes state media striking an upbeat or humorous tone, in line with President Xi Jinping’s call for “public opinion guidance”. Read the full story below:

Related: From gassy passengers to viral anthems: Beijing seeks to lighten mood amid crisis

7.09am GMT

Reports that a South Korean person has tested positive for coronavirus following a visit to Thailand are likely to cause great concern to Thai officials. The outbreak has already dealt a massive blow to Thailand’s tourism industry, which relies upon Chinese visitors.

The Tourism Authority of Thailand said it expects 2 million fewer Chinese tourists this year than last year, when 11 million visited.

Follow the latest developments as dozens more die in the province at the centre of the outbreak

• Dozens more die in province at centre of outbreak
• Chinese shares drop amid fears of virus impact
• Brazilians stranded in Wuhan issue rescue plea
• 11 more Britons to be flown home

10.44am GMT

Sixty Italians evacuated from Wuhan arrived at a military base near Rome on Monday.

A passenger who was expected to be on board the flight remained in Wuhan after coming down with a fever, Italian media reported. The group will be quarantined for up to two weeks.

10.33am GMT

As researchers are racing to develop a vaccine for the Wuhan coronavirus, the British drugmaker GSK has teamed up with the Coalition for Epidemic Preparedness Innovations (CEPI) to aid efforts to produce a vaccine.

GSK, one of the world’s biggest vaccine makers, says it will make its “adjuvant platform technology” available. An adjuvant is added to some vaccines to improve the immune response and means the amount of antigen required per dose can be reduced – allowing more vaccine doses to be produced and made available to more people, which is crucial in a pandemic.

Gaining access to GSK’s world-leading adjuvant technology is a huge step forward in developing a vaccine against the novel coronavirus 2019-nCoV. Coupling GSK’s adjuvant systems with the pioneering platform technology we are funding has the potential to make more vaccine available more rapidly – by decreasing the dose of vaccine antigen required to protect each individual.”

Related: Researchers make strides in race to create coronavirus vaccine